CN Bio Innovations, a Vanderbilt licensee, and FDA sign collaborative agreement using Organ-on-Chip technologies

• 
• 
• 
• 

CN Bio Innovations Limited announces that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research.

FDA and CN Bio will collaborate to characterize the performance of CN Bio’s Organs-on-Chips as a platform for potential use in drug development and regulatory evaluation, including safety testing prior to new drugs entering clinical trials.  FDA scientists will assess the use of the devices to provide precise data about how human cells and organs interact with new drugs, and their ability to accurately predict the success of drugs prior to human clinical trials.